Publications by authors named "Viola Regondi"

Claim this Profile
I
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.
Lorenzo Castagnoli, Francesco Bonì, Martina Bigliardi, Paolo Toneguzzo, Paola A Corsetto, Viola Regondi

Sci Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness.
Tiziana Triulzi, Marta Giussani, Elisa Maffioli, Viola Regondi, Ewelina J Lorenc

NPJ Breast Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Viola Regondi

J Exp Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Viola Regondi

J Exp Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
Ilona Rybinska, Nunzia Mangano, Sandra L Romero-Cordoba, Viola Regondi, Valentina Ciravolo

Int J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.
Tiziana Triulzi, Viola Regondi, Elisabetta Venturelli, Patrizia Gasparini, Cristina Ghirelli

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.
Martina Di Modica, Giorgio Gargari, Viola Regondi, Arianna Bonizzi, Stefania Arioli

Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Anna Rossini, Marta Giussani, Francesca Ripamonti, Piera Aiello, Viola Regondi

Cancer Biol Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer.
Saumya Tiwari, Tiziana Triulzi, Sarah Holton, Viola Regondi, Biagio Paolini

Sci Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.
Tiziana Triulzi, Viola Regondi, Loris De Cecco, Maria Rosa Cappelletti, Martina Di Modica

Br J Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.
Tiziana Triulzi, Luca Forte, Viola Regondi, Martina Di Modica, Cristina Ghirelli

Oncoimmunology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.
Martina Di Modica, Viola Regondi, Marco Sandri, Marilena V Iorio, Adriana Zanetti

Cancer Lett· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Martina Di Modica, Lucia Sfondrini, Viola Regondi, Stefania Varchetta, Barbara Oliviero

Oncotarget· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maspin influences response to doxorubicin by changing the tumor microenvironment organization.
Tiziana Triulzi, Manuela Ratti, Monica Tortoreto, Cristina Ghirelli, Piera Aiello, Viola Regondi

Int J Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis